Presentation Type

Oral Presentation

Keywords

Roche Pharmaceuticals, Central Nervous System, Alzheimer's Disease, Biopharmaceutical Industry

Department

Business Administration

Major

Business Administration

Abstract

Roche is the fifth largest pharmaceutical and biotechnology company in the world with $52B in sales during 2013 and 4.9% market share in the pharmaceutical industry. Its main competitors include Novartis, Pfizer, Johnson & Johnson, Sanofi, Merck & Co., and GlaxoSmithKline. Roche’s mission is to develop treatments for medical needs that have gone unmet and to create more efficient treatment options through cutting edge research. The Central Nervous System market segment makes up 19.6% of total industry sales and includes products treating such ailments as depression, epilepsy, psychosis, and Alzheimer’s disease. Though historically Roche has been a market leader in this segment, in recent years its Share of Market (SOM) has declined. Alzheimer’s disease is a progressive degenerative illness that causes memory loss, personality changes, loss of mobility, and death. Currently 35MM people, word wide, are suffering from the disease. The greatest predictors of Alzheimer’s disease are age and genetics. Therefore the number of people infected with the disease is expected to increase dramatically in the coming years as the global populate ages. Currently there are five FDA approved treatments for the disease, however they are ineffective as the best possible outcome is an increase in life expectancy of only 12 months. The objective of this undergraduate research project is to recommend a central nervous system corporate strategy for Roche, which would involve the development of a new drug to treat Alzheimer’s disease. This strategy would help Roche to retain or even strengthen its SOM against competitors.

Faculty Mentor

Dr. Venkatachalam Seshan

Funding Source or Research Program

Academic Year Undergraduate Research Initiative

Presentation Session

Session C

Location

Rockwell Academic Center 170

Start Date

3-4-2015 4:15 PM

End Date

3-4-2015 4:30 PM

Kali Jelen AYURI Deck.pdf (18440 kB)
Kali Jelen Roche Pharm AYURI Deck

Share

COinS
 
Apr 3rd, 4:15 PM Apr 3rd, 4:30 PM

Central Nervous System Strategy for Roche Pharmaceuticals

Rockwell Academic Center 170

Roche is the fifth largest pharmaceutical and biotechnology company in the world with $52B in sales during 2013 and 4.9% market share in the pharmaceutical industry. Its main competitors include Novartis, Pfizer, Johnson & Johnson, Sanofi, Merck & Co., and GlaxoSmithKline. Roche’s mission is to develop treatments for medical needs that have gone unmet and to create more efficient treatment options through cutting edge research. The Central Nervous System market segment makes up 19.6% of total industry sales and includes products treating such ailments as depression, epilepsy, psychosis, and Alzheimer’s disease. Though historically Roche has been a market leader in this segment, in recent years its Share of Market (SOM) has declined. Alzheimer’s disease is a progressive degenerative illness that causes memory loss, personality changes, loss of mobility, and death. Currently 35MM people, word wide, are suffering from the disease. The greatest predictors of Alzheimer’s disease are age and genetics. Therefore the number of people infected with the disease is expected to increase dramatically in the coming years as the global populate ages. Currently there are five FDA approved treatments for the disease, however they are ineffective as the best possible outcome is an increase in life expectancy of only 12 months. The objective of this undergraduate research project is to recommend a central nervous system corporate strategy for Roche, which would involve the development of a new drug to treat Alzheimer’s disease. This strategy would help Roche to retain or even strengthen its SOM against competitors.